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Abstract
Exit site infection (ESI) is an important clinical problem in peritoneal dialysis (PD)
patients and is a significant cause of peritonitis and catheter loss. While most ESIs are
caused by skin commensals, rising incidence of atypical and resilient organisms such
as mycobacteria, Pseudomonas and Burkholderia species has been observed. The diagnosis
and management of these emerging pathogen remain difficult and poorly defined. This
chapter highlights the evaluation and management of ESI in PD patients. The clinical
features, microbiology, and ultrasonographic findings are discussed. The general and
specific management of ESI due to different organisms will also be elaborated. ESI is
usually a clinical diagnosis, but the use of bedside ultrasound can help assess for any
collection around the cuff and tunnel tract involvement. Topical prophylaxis remains
an effective way to prevent ESI. While the majority ESIs are related to skin flora and can
be managed successfully by topical or systemic antimicrobials, clinicians should be alert
to the emergence of resistant and atypical microorganisms. Surgical treatment should
be reserved for ESI refractory to medical treatment or those with associated peritonitis.
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1. Introduction
Peritoneal dialysis (PD) is an important modality of renal replacement therapy and is gaining
popularity in both developed and developing countries [1]. While PD is associated with lower
treatment costs and better patient autonomy when compared to hemodialysis, the practice of
PD is also burdened with various infectious and noninfectious complications. PD catheter (also
known as Tenckhoff catheter) is an essential device for the performance of PD exchanges.
However, the implantation of a PD catheter is associated with infective complications such as
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exit site infection (ESI), tunnel tract infections, and peritonitis. Repeated or fulminant PD
peritonitis heralds adverse clinical outcomes such as catheter loss, peritoneal failure and patient
mortality [2–4]. Therefore, prevention of peritonitis plays a crucial role in the care of PD patients.
In this context, ESI constitutes a significant risk factor for peritonitis, and thus prevention and
appropriate management of ESI can substantially diminish the risk of PD-related peritonitis [2–
5], and thus improve overall patient outcomes.
2. Pathogenesis and microbiology of exit site infection in peritoneal
dialysis patients
In most PD patients, colonization with microorganisms occurs shortly after the implantation
of PD catheter. Colonization does not equate clinical infection, but predisposes PD patients to
ESI, especially after exit site traumatization. Bacterial colonization of exit site is frequently
followed by formation of biofilm, which promote further bacterial growth and void the
colonizing microorganisms from antimicrobial treatments. The organisms that colonize the
exit site are often the same pathogens responsible for ESI [6]. Common pathogens to cause ESI
in PD patients include Staphylococcus aureus, coagulase negative staphylococcus (CNS), Pseudo‐
monas aeruginosa, and other Gram-negative bacilli [2]. With the widespread application of exit
site prophylaxis, there is a shift in causative agents for ESI. For instance, some studies have
suggested that the use of mupirocin or gentamicin ointment may predispose patients to fungal
exit site infections [7, 8]. There is also emergence of exotic organisms such as atypical myco‐
bacteria, corynebacteria as well as Burkholderia species to cause ESI [2, 9–11]. Furthermore, the
development of antibiotics resistance remains an important concern in the management of ESI.
2.1. Staphylococcus aureus
S. aureus is a Gram-positive coccus and a common skin commensal. It is one of the commonest
causative agents for ESI in PD patients, and accounts for over 50% of ESI cases [6]. In general,
S. aureus can be categorized into methicillin-sensitive S. aureus (MSSA) and methicillin-resistant
S. aureus (MRSA). Methicillin-resistant S. aureus (MRSA) refer to strains of S. aureus that have
developed resistance to β-lactam antibiotics including penicillinase-resistant penicillins
(methicillin, cloxacillin, etc.) and cephalosporins. One national survey conducted among
nephrology units in the United States has reported that over 40% of isolates of S. aureus belong
to the MRSA strains [12]. Diabetes mellitus, increased age, immunocompromised state and
protracted hospital stay are common and important risk factors for MRSA infections [13].
MRSA is a frequent cause of ESI, tunnel tract infection and peritonitis in PD patients, and is
associated with appreciable morbidity and mortality in dialysis populations [14–16].
2.2. Coagulase-negative staphylococcus
Coagulase-negative staphylococci (CNS) are skin flora that can cause ESI. Staphylococcus epider‐
midis and Staphylococcus saprophyticus are common CNS, and the former accounts for roughly
20% of all ESI [6]. Other CNS that can cause ESI include Staphylococcus lugdunensis and
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Staphylococcus warneri [17]. While most CNS will respond to first-generation cephalosporins or
penicillinase-resistant penicillin, there is growing prevalence for methicillin-resistant CNS
(MRCNS).
2.3. Other Gram-positive organisms
Corynebacterium species (e.g., diphtheroids) are common skin commensals which exhibit
intrinsic resistance to many commonly used antibiotics such as β-lactams, clindamycin,
macrolides, quinolones and gentamicin [18]. Other Gram-positive bacteria that can be
associated with ESI include streptococcal species (e.g., Streptococcus sanguinus) and enterococ‐
cal species [2, 17].
2.4. Pseudomonas aeruginosa
P. aeruginosa is a Gram-negative rod-shaped bacterium that commonly causes ESI in PD
patients and is responsible for 8% of all ESI [6]. P. aeruginosa is a notorious for its ubiquity and
intrinsic resistance to many commonly used antibiotics. Furthermore, P. aeruginosa is also well
recognized for biofilm formation which contributes the persistence of infection. With these
properties, P. aeruginosa often causes refractory ESI, requires prolonged antibiotics and is also
associated with high risk of catheter loss [19, 20]. Moreover, around 20% of patients develop
P. aeruginosa peritonitis several months after the resolution of ESI [19].
2.5. Other Gram-negative organisms and anaerobes
Gram-negative bacilli are also important causes of ESI, and Escherichia coli accounts for about
4% of all cases of ESI [6]. Other Gram-negative organisms that can cause ESI include Klebsiella
pneumoniae, Enterobacter species and Proteus mirabilis [17]. The emergence of extended spectrum
β-lactamase (ESBL)-producing Gram-negative bacilli is an escalating threat in the management
of ESI. Other emerging pathogens to cause ESI include Burkholderia cepacia, which is a hardy
nonfermenting Gram-negative organism [10, 11]. Its intrinsic resistance to multiple commer‐
cially available antibiotics and easy transmissibility renders it a growing problem in dialysis
units. Although, B. cepacia is associated with low risk of tunnel tract infection or peritonitis, it
is associated with a high rate of recurrence after successful antibiotics treatment [11]. Occa‐
sionally, anaerobes (e.g., micrococcus) can be also isolated from ESI in PD patients [17].
2.6. Mycobacterium
Rapidly growing atypical mycobacteria are more frequent causative agents for ESI than
Mycobacterium tuberculosis. Atypical mycobacteria that commonly cause ESI include M.
chelonae, M. fortuitum and M. abscessus [9, 21]. It is postulated that the use of gentamicin may
predispose patients to atypical mycobacterial infections due to selection pressure on other
microorganisms [9]. ESI due to atypical mycobacteria require prolonged systemic antimicro‐
bial treatments and is associated with high rates of catheter loss [21]. Although dialysis patients
are at risk of M. tuberculosis infection, ESI due to M. tuberculosis is not common and usually
occur as part of a disseminated tuberculosis infection.




Fungal ESI is a rare cause of ESI, and Candida species (being skin flora) are the commonest
fungi isolated in this context. Some literatures have suggested that the use of mupirocin or
gentamicin ointment prophylaxis might increase the risk of fungal ESI [7, 8].
3. Clinical features and evaluation of exit site infection in peritoneal
dialysis patients
ESI is characterized by purulent discharge from the exit site, and with or without erythema or
induration at the exit site [2, 22]. Although erythema around the PD catheter in the absence of
purulent discharge may represent early signs of ESI, this can also be normal skin reaction to
recently implanted PD catheter or exit site traumatization. The presence of crust around the
exit site or positive cultures from exit site without signs of inflammation, however, does not
indicate an ESI. The spectrum of severity of ESI can range from increased crust formation, to
erythema around the exit site, to serous or purulent discharge, to abscess formation, and to
tunnel tract involvement. In this context, different grading systems have been proposed to
document the clinical severity of ESI [22, 23]. Assessment of the exit site involves gross
inspection of the exit site, palpation of the tunnel tract and expression of discharge from the
exit site. The discharge should be sent for microbiological examination (Gram smear, culture
and sensitivity pattern), which can guide further treatment decisions. Ultrasonography has
also been used to assess ESI, especially with regard to local collections and tunnel tract
involvements [24]. In this context, sonolucent zone (>1 mm thick) surrounding the external
cuff after a course of appropriate antimicrobial therapy and the involvement of the internal
cuff portends adverse clinical outcomes [24].
4. Prevention of exit site infection in peritoneal dialysis patients
Proper care of the exit site constitutes an integral component in the prevention of ESI. In the
early postoperative period (~first 2 weeks), the exit site should be kept dry until it is well healed
[22]. The exit site should be covered with sterile dressing and the change of dressing should
be performed by experienced nursing staff before the patient is properly trained. After
completion of PD training, the patient should be able to clean the exit site with antiseptic agents
(e.g., povidone iodine or chlorhexidine) on daily or alternate day basis, and the exit site be
constantly covered with sterile dressings [22].
Hand hygiene is a key measure to decrease ESI in PD patients. Good hand hygiene practices
should be undertaken by patients, helpers and healthcare providers during routine handling
of the PD catheter and its exit site [25]. In this regard, 70% alcohol-based hand rub is the most
effective hand-sanitizing agent to be used before and after the handing of PD catheter and its
exit site [26]. Alternative hand-sanitizing agents include antimicrobial-containing (e.g., 4%
chlorhexidine) soap [26].
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S. aureus is a frequent pathogen to cause ESI, and associated with PD-related peritonitis and
catheter loss [27]. The application of exit site prophylaxis can markedly diminish the PD-
related S. aureus infection and thus should be undertaken in all PD patients [7, 28]. In this
context, topical mupirocin has demonstrated its effectiveness as prophylaxis for S. aureus ESI
[7, 28–32]. In one previous observational study involving more than 700 new PD patients, the
use of topical mupirocin as exit site prophylaxis leads to a significant reduction in both ESI
(0.168 vs. 0.156 episodes per patient-year) and peritonitis (0.443 vs. 0.339 episodes per patient-
year) [32]. Subsequent meta-analyses corroborated these observations and highlighted that
topical mupirocin was associated with 60–70% decrease in both S. aureus ESI and peritonitis
[29, 33]. The administration of intranasal mupirocin has been investigated in a large multi-
center trial, which showed that intranasal mupirocin in PD patients with confirmed nasal S.
aureus carriage prevent ESI but not peritonitis [34]. However, data that compared intranasal
versus exit-site route of mupirocin prophylaxis are lacking.
Although the exit site prophylaxis with mupirocin has curbed S. aureus infection in PD patients,
P. aeruginosa remains an important culprit for ESI. Gentamicin is an aminoglycoside that
demonstrates good activity against both S. aureus and P. aeruginosa. The application of daily
gentamicin ointment versus daily mupirocin ointment as exit site prophylaxis has been
investigated in a multi-center double-blind randomized clinical trial. The results demonstrated
that gentamicin and mupirocin are similarly effective in preventing S. aureus ESI but the former
conferred an advantage on preventing Pseudomonas ESI. Notwithstanding, liberal administra‐
tion of gentamicin ointment as exit site prophylaxis might predispose PD patients to fungal
ESI. Other novel prophylactic therapies for PD exit site include MediHoney and Polysporin
triple (bacitracin, gramicidin and polymixin B) ointment [8, 35].
5. Management of exit site infection in peritoneal dialysis patients
5.1. General principles (Figure 1)
Exit site care and local dressing constitutes the cornerstone in the management of ESI. Topical
antiseptics (e.g., mupirocin, gentamicin ointment) are all viable options for dressing of exit
sites. Other alternatives such as hypertonic saline solution can be considered in selected cases
(e.g., P. aeruginosa ESI). Empirical oral or intravenous antibiotics should be initiated after
appropriate microbiological samples have been obtained and should always cover S. aureus.
However, the choice of empirical antimicrobial treatment should also take into consideration
the likely organism involved, medical background of the patients, previous culture and
resistance profile of organisms isolated from the patient and the local antibiotics susceptibility/
resistance pattern [2]. In general, first-generation cephalosporins or penicillinase-resistant
penicillins can be used as initial treatment for ESI in PD patients [2]. The choice of antibiotics
and duration of treatment can be further modified when the culture identity and the suscept‐
ibility/resistance profile are available. Trimming/shaving of the external cuff can be considered
if the external cuff is partially or fully protruding outside the exit site [6, 36] (Figure 2).
Catheters should be removed when there is recurrent infection due to the same organism, ESI
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refractory to medical therapy, presence of tunnel tract abscess or associated peritonitis [2].
Most patients will require temporary hemodialysis while pending catheter reinsertion,
simultaneous removal and reimplantation of PD catheter can be considered in selected cases
to avoid bridging hemodialysis [37]. However, such approach is not advisable when there is
also concomitant active peritonitis.
Figure 1. Management algorithm for exit site infection in peritoneal dialysis patients.
Figure 2. PD catheter after shaving of external catheter.
5.2. Management of exit site infection due to specific organisms
5.2.1. Methicillin-sensitive or resistant S. aureus
First-generation cephalosporins (e.g., cephazolin) or penicillinase-resistant penicillins (e.g.,
cloxacillin) can be used in MSSA ESI [2]. Parenteral vancomycin has established clinical efficacy
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in the treatment of MRSA ESI, tunnel tract tunnel infection and peritonitis in PD patients [2].
In this context, intravenous (IV) vancomycin (1 g every 5–7 days for a minimum of 14 days) is
a standard treatment of MRSA exit site or tunnel tract infection in PD patients [2]. However,
rising MIC to vancomycin remains a valid concern for the use of vancomycin in MRSA
infection. Other viable choices for MRSA infections in PD patients include teicoplanin,
daptomycin, linezolid, tigecycline, and quinupristin-dalfopristin. Teicoplanin is a glycopep‐
tide that exhibits activity and efficacy profile resembling vancomycin, and has the merit of
longer half-life and superior tolerability than vancomycin. Daptomycin is an approved
treatment of complicated MRSA soft-tissue infections and bacteremia (with or without
infection endocarditis) in a dosage of 6 mg/kg/day [38, 39]. In CKD stage 4 or 5 patients, the
dosage of daptomycin should remain unchanged but the frequency be reduced to every 48
hours [40]. Linezolid (600 mg B.I.D., IV or PO) can be used for the treatment of MRSA skin
infection as well as community- or hospital-acquired MRSA pneumonia [41, 42]. No dosage
modification is required for linezolid in dialysis patients but one should be aware of the side
effects such as myelosuppression and lactic acidosis [42]. Tigecycline demonstrates promising
in vitro activity against most MRSA strains and is an approved treatment for MRSA skin and
intra-abdominal infections [43–45]. No dosage reduction is required for the use of tigecycline
in PD patients is another added advantage. Quinupristin-dalfopristin is an approved treatment
for MRSA soft-tissue infections with no dosage modification in renal failure patients. However,
its data in PD patients are relatively scarce [40]. Clindamycin is not recommended for MRSA
ESI in PD patients due to its unreliable activity against MRSA acquired nosocomially [42, 46].
Other emerging antimicrobials for MRSA infections include lipoglycopeptides dalbavancin,
telavancin and oritavancin as well as newer generation cephalosporins such as ceftobiprole
and ceftaroline [43, 44, 47]. The data on these novel agents for MRSA ESI, however, remain
limited in PD patients.
5.2.2. Pseudomonas aeruginosa
Topical treatments (e.g., gentamicin ointment) can be used as adjunctive treatment for mild
P. aeruginosa ESI [2]. Other alternatives include hypertonic saline although such therapy is not
a standard practice [22]. Previous studies have reported the efficacy of oral fluoroquinolones
(e.g., ciprofloxacin or levofloxacin) for the treatment of ESI due to P. aeruginosa [2, 19, 48].
Current standard-of-care therapy for the ESI consisted of oral fluoroquinolones (e.g., cipro‐
floxacin 500 mg B.I.D) and local application of antiseptic agents to the exit site [2, 19, 48].
Intravenous antibiotics should be used in severe ESI due to P. aeruginosa [2]. Choices of
intravenous antibiotics include third- or fourth-generation cephalosporins (e.g., ceftazidime
and cefepime), ticarcillin/clavulanate, piperacillin (with or without tazobactam) and carbape‐
nems. The optimal duration of antibiotics treatment should be at least 2–3 weeks [2]. Catheter
removal should be considered in cases with refractory ESI which respond poorly to medical
treatment or associated peritonitis [2]. Up to 50–80% of patients with ESI due to P. aeruginosa
ESI respond to medical therapy, while approximately 20–36% would require catheter removal
[19, 48].
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5.2.3. Other Gram-negative organisms
In general, ESI due to Gram-negative organisms are susceptible to second- or third-generation
cepholosporins [2, 22]. However, there is increasing prevalence of ESBL-producing Gram-
negative organisms. Carbapenems should be considered in patients with previous history of
ESBL-producing organisms or when the ESI do not respond to second- or third-generation
cephalosporins [2]. B. cepacia are generally susceptible to ceftazidime (95.5%), piperacillin/
tazobactam (95.5%) and pipercillin (90.9%) [11]. While most patients with B. cepacia ESI will
respond to medical therapy, a high rate of recurrence is observed. Similar to P. aeruginosa ESI,
the duration of treatment for B. cepacia ESI should be extended up to 3 weeks.
5.2.4. Mycobacterium
The treatment regimen for atypical mycobacterium ESI is dependent on the organisms
identified as well as the susceptibility/resistance profiles. In general, the regimen should
consist of at least two or more antimycobacterial agents (e.g., parenteral aminoglycosides,
fluoroquinolones, tetracyclines and macrolides), and prolonged therapy is generally required
[2, 21]. In this context, a combination of oral fluoroquinolones, tetracyclines (doxycycline or
minocycline), macrolides (clarithromycin or azithromycin) or cotrimoxazole can be adminis‐
tered for M. fortuitum ESI [21, 49]. Clarithromycin, in combination with doxycycline or
ciprofloxacin, is commonly used in localities where most M. chelonae are susceptible to
macrolides [21]. The treatment regimen for M. abscessus should comprise clarithromycin plus
either amikacin or high-dose cefoxitin [21]. The prolonged administration of aminoglycosides
and macrolides is associated with ototoxicity and cardiac arrhythmia (QT prolongation) in PD
patients. Approximately 44% of patients will respond to medical therapy and catheter removal
should be considered in patients with refractory mycobacterial ESI.
5.2.5. Fungal exit site infection
Fungal ESI is rare clinical entity and there are limited data regarding the optimal management
of fungal ESI. It is important to exclude contamination when fungus is isolated from the exit
site, and removal of PD catheter should be considered if there is established fungal ESI to avoid
fungal peritonitis.
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